Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Shah

Showing results (271-280 of 296) with videos related to

Pageof 30
Sort By:
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
The New England Journal of Medicine|January 31, 2024
CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary AngioedemaHilary J Longhurst, Karen Lindsay, Remy S Petersen, et al.
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
JAMA Network Open|August 30, 2021
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint InhibitorsPavlos Msaouel, Clara Oromendia, Arlene O Siefker-Radtke, et al.
Cancer Discovery|September 5, 2013
Therapeutic synergy between microRNA and siRNA in ovarian cancer treatmentMasato Nishimura, Eun-Jung Jung, Maitri Y Shah, et al.
European Urology|March 1, 2026
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic ModelChad Tang, Aaron Seo, Alexander D Sherry, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
Nature Communications|May 10, 2023
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinomaJose A Karam, Pavlos Msaouel, Cara L Haymaker, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Pageof 30

Showing results (271-280 of 296) with videos related to

Sort By:
Pageof 30
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
The New England Journal of Medicine|January 31, 2024
CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary AngioedemaHilary J Longhurst, Karen Lindsay, Remy S Petersen, et al.
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
JAMA Network Open|August 30, 2021
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint InhibitorsPavlos Msaouel, Clara Oromendia, Arlene O Siefker-Radtke, et al.
Cancer Discovery|September 5, 2013
Therapeutic synergy between microRNA and siRNA in ovarian cancer treatmentMasato Nishimura, Eun-Jung Jung, Maitri Y Shah, et al.
European Urology|March 1, 2026
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic ModelChad Tang, Aaron Seo, Alexander D Sherry, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
Nature Communications|May 10, 2023
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinomaJose A Karam, Pavlos Msaouel, Cara L Haymaker, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Pageof 30